An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid
Radiosensitization of glioblastoma is a major ambition to increase the survival of this incurable cancer. The 5-aminolevulinic acid (5-ALA) is metabolized by the heme biosynthesis pathway. 5-ALA overload leads to the accumulation of the intermediate fluorescent metabolite protoporphyrin IX (PpIX) wi...
Gespeichert in:
Veröffentlicht in: | Cancers 2022-08, Vol.14 (17), p.4244 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 17 |
container_start_page | 4244 |
container_title | Cancers |
container_volume | 14 |
creator | Dupin, Charles Sutter, Jade Amintas, Samuel Derieppe, Marie-Alix Lalanne, Magalie Coulibaly, Soule Guyon, Joris Daubon, Thomas Boutin, Julian Blouin, Jean-Marc Richard, Emmanuel Moreau-Gaudry, François Bedel, Aurélie Vendrely, Véronique Dabernat, Sandrine |
description | Radiosensitization of glioblastoma is a major ambition to increase the survival of this incurable cancer. The 5-aminolevulinic acid (5-ALA) is metabolized by the heme biosynthesis pathway. 5-ALA overload leads to the accumulation of the intermediate fluorescent metabolite protoporphyrin IX (PpIX) with a radiosensitization potential, never tested in a relevant model of glioblastoma. We used a patient-derived tumor cell line grafted orthotopically to create a brain tumor model. We evaluated tumor growth and tumor burden after different regimens of encephalic multifractionated radiation therapy with or without 5-ALA. A fractionation scheme of 5 × 2 Gy three times a week resulted in intermediate survival [48–62 days] compared to 0 Gy (15–24 days), 3 × 2 Gy (41–47 days) and, 5 × 3 Gy (73–83 days). Survival was correlated to tumor growth. Tumor growth and survival were similar after 5 × 2 Gy irradiations, regardless of 5-ALA treatment (RT group (53–67 days), RT+5-ALA group (40–74 days), HR = 1.57, p = 0.24). Spheroid growth and survival were diminished by radiotherapy in vitro, unchanged by 5-ALA pre-treatment, confirming the in vivo results. The analysis of two additional stem-like patient-derived cell lines confirmed the absence of radiosensitization by 5-ALA. Our study shows for the first time that in a preclinical tumor model relevant to human glioblastoma, treated as in clinical routine, 5-ALA administration, although leading to important accumulation of PpIX, does not potentiate radiotherapy. |
doi_str_mv | 10.3390/cancers14174244 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9454704</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A745271161</galeid><sourcerecordid>A745271161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-72706b3b97e75bec2884b0f7cf40e72cca9626612c4587b782eb182f688a91e03</originalsourceid><addsrcrecordid>eNptkk1r3DAQhk1paUKac6-GXtqDE31ZI18KJrRJYEsgpGchy3KsYEtbSd6w_74yG9pmqXSQmHned_QxRfERowtKG3SpldMmRMwwMMLYm-KUICAV5w17-8_-pDiP8QnlQSkGDu-LE8oRAAh6WujWlXchjT75rdXlD9-bqfRDeT1Z300qJj-r8jaW9ybamJRLZfLlveqt7_dOzVnyMJqgtvvy2aaxrKt2ts5vzG6ZrMvZVtv-Q_FuUFM05y_rWfHz-7eHq5tqc3d9e9VuKs2aJlVAAPGOdg0YqDujiRCsQwPogSEDRGvVcMI5JprVAjoQxHRYkIELoRpsED0rvh58t0s3m14bl4Ka5DbYWYW99MrK1xlnR_nod7JhNQPEssGXg8F4JLtpN3KNISooYozucGY_vxQL_tdiYpKzjdpMk3LGL1ESwETUNdAmo5-O0Ce_BJefYqUwqYEL-Es9qslI6wafz6hXU9kCq1eSr2Uv_kPl2Zv8Gd6Zweb4K8HlQaCDjzGY4c_FMJJrG8mjNqK_Aaert_o</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2711257687</pqid></control><display><type>article</type><title>An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Dupin, Charles ; Sutter, Jade ; Amintas, Samuel ; Derieppe, Marie-Alix ; Lalanne, Magalie ; Coulibaly, Soule ; Guyon, Joris ; Daubon, Thomas ; Boutin, Julian ; Blouin, Jean-Marc ; Richard, Emmanuel ; Moreau-Gaudry, François ; Bedel, Aurélie ; Vendrely, Véronique ; Dabernat, Sandrine</creator><creatorcontrib>Dupin, Charles ; Sutter, Jade ; Amintas, Samuel ; Derieppe, Marie-Alix ; Lalanne, Magalie ; Coulibaly, Soule ; Guyon, Joris ; Daubon, Thomas ; Boutin, Julian ; Blouin, Jean-Marc ; Richard, Emmanuel ; Moreau-Gaudry, François ; Bedel, Aurélie ; Vendrely, Véronique ; Dabernat, Sandrine</creatorcontrib><description>Radiosensitization of glioblastoma is a major ambition to increase the survival of this incurable cancer. The 5-aminolevulinic acid (5-ALA) is metabolized by the heme biosynthesis pathway. 5-ALA overload leads to the accumulation of the intermediate fluorescent metabolite protoporphyrin IX (PpIX) with a radiosensitization potential, never tested in a relevant model of glioblastoma. We used a patient-derived tumor cell line grafted orthotopically to create a brain tumor model. We evaluated tumor growth and tumor burden after different regimens of encephalic multifractionated radiation therapy with or without 5-ALA. A fractionation scheme of 5 × 2 Gy three times a week resulted in intermediate survival [48–62 days] compared to 0 Gy (15–24 days), 3 × 2 Gy (41–47 days) and, 5 × 3 Gy (73–83 days). Survival was correlated to tumor growth. Tumor growth and survival were similar after 5 × 2 Gy irradiations, regardless of 5-ALA treatment (RT group (53–67 days), RT+5-ALA group (40–74 days), HR = 1.57, p = 0.24). Spheroid growth and survival were diminished by radiotherapy in vitro, unchanged by 5-ALA pre-treatment, confirming the in vivo results. The analysis of two additional stem-like patient-derived cell lines confirmed the absence of radiosensitization by 5-ALA. Our study shows for the first time that in a preclinical tumor model relevant to human glioblastoma, treated as in clinical routine, 5-ALA administration, although leading to important accumulation of PpIX, does not potentiate radiotherapy.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14174244</identifier><identifier>PMID: 36077783</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Aminolevulinic acid ; Blood-brain barrier ; Brain cancer ; Brain tumors ; Cancer ; Care and treatment ; Cell adhesion & migration ; Cell culture ; Enzymes ; Glioblastoma ; Glioblastoma multiforme ; Heme ; Life Sciences ; Methods ; Oral administration ; Patient outcomes ; Patients ; Porphyrins ; Proteins ; Protoporphyrin ; Protoporphyrin IX ; Radiation therapy ; Radiosensitization ; Radiotherapy ; Santé publique et épidémiologie ; Spheroids ; Surgery ; Tumors</subject><ispartof>Cancers, 2022-08, Vol.14 (17), p.4244</ispartof><rights>COPYRIGHT 2022 MDPI AG</rights><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-72706b3b97e75bec2884b0f7cf40e72cca9626612c4587b782eb182f688a91e03</citedby><cites>FETCH-LOGICAL-c499t-72706b3b97e75bec2884b0f7cf40e72cca9626612c4587b782eb182f688a91e03</cites><orcidid>0000-0001-6692-2890 ; 0000-0002-0319-7617 ; 0000-0003-1813-3939 ; 0000-0001-8372-9945</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454704/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454704/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://hal.science/hal-03830443$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Dupin, Charles</creatorcontrib><creatorcontrib>Sutter, Jade</creatorcontrib><creatorcontrib>Amintas, Samuel</creatorcontrib><creatorcontrib>Derieppe, Marie-Alix</creatorcontrib><creatorcontrib>Lalanne, Magalie</creatorcontrib><creatorcontrib>Coulibaly, Soule</creatorcontrib><creatorcontrib>Guyon, Joris</creatorcontrib><creatorcontrib>Daubon, Thomas</creatorcontrib><creatorcontrib>Boutin, Julian</creatorcontrib><creatorcontrib>Blouin, Jean-Marc</creatorcontrib><creatorcontrib>Richard, Emmanuel</creatorcontrib><creatorcontrib>Moreau-Gaudry, François</creatorcontrib><creatorcontrib>Bedel, Aurélie</creatorcontrib><creatorcontrib>Vendrely, Véronique</creatorcontrib><creatorcontrib>Dabernat, Sandrine</creatorcontrib><title>An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid</title><title>Cancers</title><description>Radiosensitization of glioblastoma is a major ambition to increase the survival of this incurable cancer. The 5-aminolevulinic acid (5-ALA) is metabolized by the heme biosynthesis pathway. 5-ALA overload leads to the accumulation of the intermediate fluorescent metabolite protoporphyrin IX (PpIX) with a radiosensitization potential, never tested in a relevant model of glioblastoma. We used a patient-derived tumor cell line grafted orthotopically to create a brain tumor model. We evaluated tumor growth and tumor burden after different regimens of encephalic multifractionated radiation therapy with or without 5-ALA. A fractionation scheme of 5 × 2 Gy three times a week resulted in intermediate survival [48–62 days] compared to 0 Gy (15–24 days), 3 × 2 Gy (41–47 days) and, 5 × 3 Gy (73–83 days). Survival was correlated to tumor growth. Tumor growth and survival were similar after 5 × 2 Gy irradiations, regardless of 5-ALA treatment (RT group (53–67 days), RT+5-ALA group (40–74 days), HR = 1.57, p = 0.24). Spheroid growth and survival were diminished by radiotherapy in vitro, unchanged by 5-ALA pre-treatment, confirming the in vivo results. The analysis of two additional stem-like patient-derived cell lines confirmed the absence of radiosensitization by 5-ALA. Our study shows for the first time that in a preclinical tumor model relevant to human glioblastoma, treated as in clinical routine, 5-ALA administration, although leading to important accumulation of PpIX, does not potentiate radiotherapy.</description><subject>Aminolevulinic acid</subject><subject>Blood-brain barrier</subject><subject>Brain cancer</subject><subject>Brain tumors</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Cell adhesion & migration</subject><subject>Cell culture</subject><subject>Enzymes</subject><subject>Glioblastoma</subject><subject>Glioblastoma multiforme</subject><subject>Heme</subject><subject>Life Sciences</subject><subject>Methods</subject><subject>Oral administration</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Porphyrins</subject><subject>Proteins</subject><subject>Protoporphyrin</subject><subject>Protoporphyrin IX</subject><subject>Radiation therapy</subject><subject>Radiosensitization</subject><subject>Radiotherapy</subject><subject>Santé publique et épidémiologie</subject><subject>Spheroids</subject><subject>Surgery</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1r3DAQhk1paUKac6-GXtqDE31ZI18KJrRJYEsgpGchy3KsYEtbSd6w_74yG9pmqXSQmHned_QxRfERowtKG3SpldMmRMwwMMLYm-KUICAV5w17-8_-pDiP8QnlQSkGDu-LE8oRAAh6WujWlXchjT75rdXlD9-bqfRDeT1Z300qJj-r8jaW9ybamJRLZfLlveqt7_dOzVnyMJqgtvvy2aaxrKt2ts5vzG6ZrMvZVtv-Q_FuUFM05y_rWfHz-7eHq5tqc3d9e9VuKs2aJlVAAPGOdg0YqDujiRCsQwPogSEDRGvVcMI5JprVAjoQxHRYkIELoRpsED0rvh58t0s3m14bl4Ka5DbYWYW99MrK1xlnR_nod7JhNQPEssGXg8F4JLtpN3KNISooYozucGY_vxQL_tdiYpKzjdpMk3LGL1ESwETUNdAmo5-O0Ce_BJefYqUwqYEL-Es9qslI6wafz6hXU9kCq1eSr2Uv_kPl2Zv8Gd6Zweb4K8HlQaCDjzGY4c_FMJJrG8mjNqK_Aaert_o</recordid><startdate>20220831</startdate><enddate>20220831</enddate><creator>Dupin, Charles</creator><creator>Sutter, Jade</creator><creator>Amintas, Samuel</creator><creator>Derieppe, Marie-Alix</creator><creator>Lalanne, Magalie</creator><creator>Coulibaly, Soule</creator><creator>Guyon, Joris</creator><creator>Daubon, Thomas</creator><creator>Boutin, Julian</creator><creator>Blouin, Jean-Marc</creator><creator>Richard, Emmanuel</creator><creator>Moreau-Gaudry, François</creator><creator>Bedel, Aurélie</creator><creator>Vendrely, Véronique</creator><creator>Dabernat, Sandrine</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6692-2890</orcidid><orcidid>https://orcid.org/0000-0002-0319-7617</orcidid><orcidid>https://orcid.org/0000-0003-1813-3939</orcidid><orcidid>https://orcid.org/0000-0001-8372-9945</orcidid></search><sort><creationdate>20220831</creationdate><title>An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid</title><author>Dupin, Charles ; Sutter, Jade ; Amintas, Samuel ; Derieppe, Marie-Alix ; Lalanne, Magalie ; Coulibaly, Soule ; Guyon, Joris ; Daubon, Thomas ; Boutin, Julian ; Blouin, Jean-Marc ; Richard, Emmanuel ; Moreau-Gaudry, François ; Bedel, Aurélie ; Vendrely, Véronique ; Dabernat, Sandrine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-72706b3b97e75bec2884b0f7cf40e72cca9626612c4587b782eb182f688a91e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aminolevulinic acid</topic><topic>Blood-brain barrier</topic><topic>Brain cancer</topic><topic>Brain tumors</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Cell adhesion & migration</topic><topic>Cell culture</topic><topic>Enzymes</topic><topic>Glioblastoma</topic><topic>Glioblastoma multiforme</topic><topic>Heme</topic><topic>Life Sciences</topic><topic>Methods</topic><topic>Oral administration</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Porphyrins</topic><topic>Proteins</topic><topic>Protoporphyrin</topic><topic>Protoporphyrin IX</topic><topic>Radiation therapy</topic><topic>Radiosensitization</topic><topic>Radiotherapy</topic><topic>Santé publique et épidémiologie</topic><topic>Spheroids</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dupin, Charles</creatorcontrib><creatorcontrib>Sutter, Jade</creatorcontrib><creatorcontrib>Amintas, Samuel</creatorcontrib><creatorcontrib>Derieppe, Marie-Alix</creatorcontrib><creatorcontrib>Lalanne, Magalie</creatorcontrib><creatorcontrib>Coulibaly, Soule</creatorcontrib><creatorcontrib>Guyon, Joris</creatorcontrib><creatorcontrib>Daubon, Thomas</creatorcontrib><creatorcontrib>Boutin, Julian</creatorcontrib><creatorcontrib>Blouin, Jean-Marc</creatorcontrib><creatorcontrib>Richard, Emmanuel</creatorcontrib><creatorcontrib>Moreau-Gaudry, François</creatorcontrib><creatorcontrib>Bedel, Aurélie</creatorcontrib><creatorcontrib>Vendrely, Véronique</creatorcontrib><creatorcontrib>Dabernat, Sandrine</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dupin, Charles</au><au>Sutter, Jade</au><au>Amintas, Samuel</au><au>Derieppe, Marie-Alix</au><au>Lalanne, Magalie</au><au>Coulibaly, Soule</au><au>Guyon, Joris</au><au>Daubon, Thomas</au><au>Boutin, Julian</au><au>Blouin, Jean-Marc</au><au>Richard, Emmanuel</au><au>Moreau-Gaudry, François</au><au>Bedel, Aurélie</au><au>Vendrely, Véronique</au><au>Dabernat, Sandrine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid</atitle><jtitle>Cancers</jtitle><date>2022-08-31</date><risdate>2022</risdate><volume>14</volume><issue>17</issue><spage>4244</spage><pages>4244-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Radiosensitization of glioblastoma is a major ambition to increase the survival of this incurable cancer. The 5-aminolevulinic acid (5-ALA) is metabolized by the heme biosynthesis pathway. 5-ALA overload leads to the accumulation of the intermediate fluorescent metabolite protoporphyrin IX (PpIX) with a radiosensitization potential, never tested in a relevant model of glioblastoma. We used a patient-derived tumor cell line grafted orthotopically to create a brain tumor model. We evaluated tumor growth and tumor burden after different regimens of encephalic multifractionated radiation therapy with or without 5-ALA. A fractionation scheme of 5 × 2 Gy three times a week resulted in intermediate survival [48–62 days] compared to 0 Gy (15–24 days), 3 × 2 Gy (41–47 days) and, 5 × 3 Gy (73–83 days). Survival was correlated to tumor growth. Tumor growth and survival were similar after 5 × 2 Gy irradiations, regardless of 5-ALA treatment (RT group (53–67 days), RT+5-ALA group (40–74 days), HR = 1.57, p = 0.24). Spheroid growth and survival were diminished by radiotherapy in vitro, unchanged by 5-ALA pre-treatment, confirming the in vivo results. The analysis of two additional stem-like patient-derived cell lines confirmed the absence of radiosensitization by 5-ALA. Our study shows for the first time that in a preclinical tumor model relevant to human glioblastoma, treated as in clinical routine, 5-ALA administration, although leading to important accumulation of PpIX, does not potentiate radiotherapy.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>36077783</pmid><doi>10.3390/cancers14174244</doi><orcidid>https://orcid.org/0000-0001-6692-2890</orcidid><orcidid>https://orcid.org/0000-0002-0319-7617</orcidid><orcidid>https://orcid.org/0000-0003-1813-3939</orcidid><orcidid>https://orcid.org/0000-0001-8372-9945</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2072-6694 |
ispartof | Cancers, 2022-08, Vol.14 (17), p.4244 |
issn | 2072-6694 2072-6694 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9454704 |
source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Aminolevulinic acid Blood-brain barrier Brain cancer Brain tumors Cancer Care and treatment Cell adhesion & migration Cell culture Enzymes Glioblastoma Glioblastoma multiforme Heme Life Sciences Methods Oral administration Patient outcomes Patients Porphyrins Proteins Protoporphyrin Protoporphyrin IX Radiation therapy Radiosensitization Radiotherapy Santé publique et épidémiologie Spheroids Surgery Tumors |
title | An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T20%3A33%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20Orthotopic%20Model%20of%20Glioblastoma%20Is%20Resistant%20to%20Radiodynamic%20Therapy%20with%205-AminoLevulinic%20Acid&rft.jtitle=Cancers&rft.au=Dupin,%20Charles&rft.date=2022-08-31&rft.volume=14&rft.issue=17&rft.spage=4244&rft.pages=4244-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14174244&rft_dat=%3Cgale_pubme%3EA745271161%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2711257687&rft_id=info:pmid/36077783&rft_galeid=A745271161&rfr_iscdi=true |